tazarotene has been researched along with betamethasone-17,21-dipropionate in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Hecker, D; Lebwohl, M; Worsley, J; Yueh, G | 1 |
| Chen, D; Ma, P; Yang, J; Yu, B; Yuan, L | 1 |
| Stein Gold, LF | 1 |
| Li, L; Ma, P; Qian, K; Zhang, M | 1 |
| Chen, H; Gu, J; Li, M; Liu, X; Lou, D; Sun, J; Sun, Q; Wen, H; Yang, H; Zhang, J | 1 |
| Hansen, JB; Nyholm, N; Patel, DS; Swensen, AR; Veverka, KA; Wu, JJ | 1 |
| Ayyagari, R; Glick, B; Guerin, A; Jacobson, A; Joseph, G; Kircik, L; Lin, T | 1 |
| Chen, H; Diao, Q; Gao, Y; Geng, L; He, C; He, Y; Hu, F; Ji, C; Jin, H; Jing, H; Li, L; Li, X; Li, Y; Liu, X; Lu, Q; Lu, T; Lv, C; Miao, G; Shi, J; Shi, Y; Song, J; Wang, R; Wang, X; Wang, Y; Xia, J; Xia, X; Yan, M; Yang, X; Zhang, L; Zhang, R; Zhang, S; Zhang, X; Zheng, M; Zhou, X | 1 |
1 review(s) available for tazarotene and betamethasone-17,21-dipropionate
| Article | Year |
|---|---|
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Topics: Administration, Cutaneous; Anthralin; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Nicotinic Acids; Patient Compliance; Pharmaceutical Vehicles; Practice Guidelines as Topic; Psoriasis; Quality of Life; Severity of Illness Index; Tacrolimus; Treatment Outcome; Vitamin D | 2016 |
1 trial(s) available for tazarotene and betamethasone-17,21-dipropionate
| Article | Year |
|---|---|
Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial.
Topics: Betamethasone; Clobetasol; Dermatologic Agents; Double-Blind Method; Humans; Neoplasm Recurrence, Local; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2020 |
7 other study(ies) available for tazarotene and betamethasone-17,21-dipropionate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation, Preclinical; Drug Incompatibility; Fluocinonide; In Vitro Techniques; Mometasone Furoate; Nicotinic Acids; Pregnadienediols; Psoriasis | 2000 |
Evaluation of change in the skin concentration of tazarotene and betamethasone dipropionate based on drug-drug interaction for transdermal drug delivery in miniature pig.
Topics: Administration, Cutaneous; Animals; Betamethasone; Dermis; Drug Delivery Systems; Drug Interactions; Epidermis; Gels; Nicotinic Acids; Ointments; Skin; Swine; Swine, Miniature; Time Factors | 2015 |
Development of a simple method for simultaneous determination of tazarotene and betamethasone dipropionate and their metabolites using LC-MS method and its application to dermatopharmacokinetic study.
Topics: Betamethasone; Cell Culture Techniques; Cell Line; Chromatography, Liquid; Humans; Limit of Detection; Linear Models; Mass Spectrometry; Models, Biological; Nicotinic Acids; Reproducibility of Results; Skin; Tissue Engineering | 2019 |
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Betamethasone; Dermatologic Agents; Drug Combinations; Erythema; Female; Humans; Male; Middle Aged; Nicotinic Acids; Pain; Prospective Studies; Pruritus; Psoriasis; Recurrence; Retreatment; Severity of Illness Index; Skin Cream | 2021 |